| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT00000635 | Herpes Simplex|HIV Infections | Drug: Trifluridine|Drug: Bacitracin zinc/Polymyxin B sulfate | National Institute of Allergy and Infectious Diseases (NIAID)|Glaxo Wellcome | |
| 2012-03-29 |
| NCT01867866 | Advanced Solid Tumors | Drug: TAS-102|Drug: Trifluridine | Taiho Oncology, Inc. | Phase 1 | 2013-06-01 | 2015-12-21 |
| NCT03031691 | Metastatic Colorectal Cancer | Drug: brontictuzumab|Drug: trifluridine/tipiracil | OncoMed Pharmaceuticals, Inc. | Phase 1 | 2017-01-01 | 2017-03-09 |
| NCT00002037 | Mycobacterium Avium-Intracellulare Infection|HIV Infections | Drug: Trifluridine | Amgen|NIH AIDS Clinical Trials Information Service | |
| 2005-06-23 |
| NCT02848443 | Metastatic Colorectal Cancer | Drug: Trifluridine/tipiracil hydrochloride (S 95005)|Drug: Oxaliplatin|Drug: Bevacizumab | Institut de Recherches Internationales Servier|Servier | Phase 1 | 2016-05-01 | 2016-11-23 |
| NCT02602327 | Colon Cancer|Rectal Cancer|Liver Metastases | Drug: Tas-102|Device: SIR-Sphere | University of California, San Francisco | Phase 1 | 2016-10-01 | 2016-12-02 |
| NCT02743221 | Metastatic Colorectal Cancer | Drug: Trifluridine/tipiracil hydrochloride (S 95005)|Drug: Capecitabine|Drug: Bevacizumab|Drug: Bevacizumab | Institut de Recherches Internationales Servier|Servier | Phase 2 | 2016-04-01 | 2017-03-16 |
| NCT00000138 | Keratitis, Herpetic|Ocular Herpes Simplex | Drug: Prednisolone Phosphate|Drug: Acyclovir | National Eye Institute (NEI) | Phase 3 | 1989-05-01 | 2009-09-16 |
| NCT00081835 | Vaccinia | Drug: NP-016 Vaccine Immune Globulin (IV-VIG) | National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC) | Phase 2 | 2004-04-19 | 2017-01-24 |
| NCT02921737 | Pancreatic Cancer | Drug: TAS-102 | University of Florida|Taiho Oncology, Inc. | Phase 2 | 2017-06-01 | 2017-03-06 |
| NCT02920476 | Squamous Cell Lung Carcinoma | Drug: TAS-102 | University of Florida|Taiho Oncology, Inc. | Phase 2 | 2017-04-01 | 2017-03-03 |
| NCT02500043 | Refractory Metastatic Gastric Cancer | Drug: TAS-102|Drug: Placebo | Taiho Oncology, Inc. | Phase 3 | 2015-12-01 | 2017-01-19 |
| NCT02301117 | Advanced Solid Tumors | Drug: TAS-102 | Taiho Oncology, Inc. | Phase 1 | 2015-01-01 | 2016-08-29 |
| NCT02301104 | Advanced Solid Tumors | Drug: TAS-102 | Taiho Oncology, Inc. | Phase 1 | 2015-01-01 | 2016-10-13 |
| NCT02261532 | Advanced or Metastatic Solid Tumors | Drug: TAS-102 | Taiho Pharmaceutical Co., Ltd. | Phase 1 | 2014-09-01 | 2017-02-05 |
| NCT01955837 | Colorectal Cancer | Drug: TAS-102|Drug: Placebo | Taiho Pharmaceutical Co., Ltd. | Phase 3 | 2013-09-01 | 2017-02-05 |
| NCT01867879 | Advanced Solid Tumors (Excluding Breast Cancer) | Drug: TAS-102|Drug: Placebo | Taiho Oncology, Inc. | Phase 1 | 2013-06-01 | 2015-11-06 |
| NCT01607957 | Colorectal Cancer | Drug: TAS-102|Drug: Placebo | Taiho Oncology, Inc. | Phase 3 | 2012-06-01 | 2015-12-21 |
| NCT02848079 | Colorectal Neoplasms | Drug: combined TAS-102 and TAS-OX | Yale University | Phase 1|Phase 2 | 2016-08-01 | 2017-01-24 |
| NCT02654639 | Metastatic Colorectal Cancer | Drug: TAS-102 and Bevacizumab | Georgetown University | Phase 2 | 2016-02-01 | 2016-08-17 |
